The Duo P201 Trial Part 2 will evaluate the safety and immune response of 2 batches of an investigational combination vaccine aimed at preventing both seasonal flu and COVID-19 infections in adults 50 to 64 years of age.
Every year, seasonal flu causes 3 to 5 million cases of severe illness and up to 650,000 deaths worldwide.1
As of January 2025, there have been more than 777 million reported COVID-19 cases worldwide.2
WHO CAN JOIN?
This clinical trial is looking for adult participants. To join, you must:
- Be 50 to 64 years of age
- Be in good health
- Not be pregnant or planning on becoming pregnant for at least 3 months following the injection visit
- Have received a flu vaccine since September 2024
OTHER CONSIDERATIONS
Prior to receiving the injection for this trial, you should:
- Not have participated in Part 1 of the Duo P201 Trial
- Not have received an investigational vaccine for seasonal flu or COVID-19 in another trial within the past year
- Not have received a seasonal flu vaccine in the past 5 months or a COVID-19 vaccine in the past 3 months
- Not have had a confirmed flu infection within 5 months or COVID-19 infection within 3 months
INTERESTED IN PARTICIPATING?
To learn more about this clinical trial, and how to join, contact the clinical trial site listed below.
Indago Research
786-772-0510
References:
1.Influenza (seasonal). World Health Organization. Updated October 3, 2023. Accessed February 5, 2025. https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)2.WHO COVID-19 dashboard. Number of COVID-19 cases reported to WHO (cumulative total). World Health Organization. Accessed February 5, 2025. https://data.who.int/dashboards/covid19/cases
